Enterprise acquisition Basepaws was acquired by Zoetis in June 2022, positioning the genetic testing capabilities within a larger animal health portfolio. Sales opportunities exist in cross-selling advanced pet health diagnostics and integration with Zoetis’ existing veterinary networks and distribution channels.
Direct-to-consumer expansion The company has launched and planned further direct-to-consumer DNA tests for dogs and cats, with multi-channel availability (website, Amazon, and other consumer channels). This creates opportunities to partner on marketing corridors, fulfillment, and data-driven consumer education programs.
Vet network tools Basepaws has rolled out genetic and oral microbiome screening tools for veterinary teams. There is potential to upsell expanded panels, subscription-based screening updates, and training services to veterinary clinics and hospital partners.
Early detection focus With emphasis on early health risk detection through genetics and microbiome data, there are sales paths for larger clinics or insurers seeking proactive care programs, risk stratification services, and integration with electronic medical records for outcome tracking.
Global pet health trend The market trend toward precision pet health and cat/dog DNA insights aligns with Zoetis’ broader portfolio. Opportunities exist to scale through co-branded campaigns, data analytics services, and expanded test offerings in regions with growing pet ownership and premium care demand.